Condensed Statements of Income (Unaudited) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2026		Sep. 30, 2025	Sep. 30, 2026		Sep. 30, 2025
Product sales	$ 8,039,951		$ 5,506,122	$ 25,583,359		$ 20,018,175
Costs of goods sold	4,484,891		3,143,024	14,933,633		11,483,181
Gross profit	3,555,060		2,363,098	10,649,726		8,534,994
Administrative expenses	1,289,291		729,421	3,698,877		2,072,682
Sales and marketing expenses	1,131,228		919,291	3,474,718		2,472,035
Product development expenses	176,771	[1]	694,311	614,111		2,283,016
Other operating income	0		0	(2,000,000)	[2]	0
Operating expenses (income), net	2,597,290		2,343,023	5,787,706		6,827,733
NET OPERATING INCOME (LOSS)	957,770		20,075	4,862,020		1,707,261
Other (expenses) income, net	(22,495)		(155,367)	(92,010)		110,118
INCOME (LOSS) BEFORE INCOME TAXES	935,275		(135,292)	4,770,010		1,817,379
Income tax (benefit) expense	(17,235)		4,456	41,237		8,264
NET INCOME (LOSS)	$ 952,510		$ (139,748)	$ 4,728,773		$ 1,809,115
Basic weighted average common shares outstanding (in shares)	9,084,358		9,045,851	9,065,181		9,019,484
Basic net income (loss) per share (in dollars per share)	$ 0.1		$ (0.02)	$ 0.52		$ 0.2
Diluted weighted average common shares outstanding (in shares)	9,297,507		9,045,851	9,188,856		9,019,484
Diluted net income (loss) per share (in dollars per share)	$ 0.1		$ (0.02)	$ 0.51		$ 0.2

[1] Includes a $0.1 million reversal of an annual regulatory sponsor fee that we were no longer required to obtain as a result of the decision to cease focus on Re-Tain®.

[2] Includes a $2.0 million settlement with a former contract manufacturer that compensated the Company for operating costs incurred in product development and contract performance related to the development of the Company’s Re-Tain® product. See Note 9 for additional discussion.